Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Operations (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Cash from Operations for 6 consecutive years, with 20832000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 41.27% to 20832000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 111000000.0, a 19.68% increase, with the full-year FY2025 number at 111000000.0, up 19.68% from a year prior.
  • Cash from Operations was 20832000.0 for Q4 2025 at Caribou Biosciences, up from 25168000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 20313000.0 in Q1 2021 to a low of 37203000.0 in Q1 2024.
  • A 5-year average of 23298800.0 and a median of 23710000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 206.7% in 2022, then surged 41.27% in 2025.
  • Caribou Biosciences' Cash from Operations stood at 21389000.0 in 2021, then decreased by 17.09% to 25044000.0 in 2022, then rose by 14.63% to 21379000.0 in 2023, then tumbled by 65.91% to 35470000.0 in 2024, then soared by 41.27% to 20832000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Cash from Operations are 20832000.0 (Q4 2025), 25168000.0 (Q3 2025), and 28275000.0 (Q2 2025).